The effect of ELOVL6 fatty acid elongase inhibition on the expression of genes associated with the metastasis of breast cancer

G. S. Zakharova, A. A. Poloznikov, L. A. Astakhova, M. P. Raigorodskaya, Z. B. Khesina, K. A. Fomicheva, A. K. Buryak, B. Ya Alekseev

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

The paper addresses the effect of a new fatty acid elongase 6 (ELOVL6) inhibitor on the migration of breast cancer cells (estrogen receptor positive MCF7 cells and estrogen receptor negative MDA-MB-231 cells) and expression of genes associated with the epithelial-mesenchymal transition, the first stage of tumor metastasis. It was shown that inhibition of the synthesis of C18 fatty acids does not change the migration activity or expression of transcription factors regulating the epithelial-mesenchymal transition. At the same time, the inhibition of ELOVL6 resulted in overexpression of genes associated with breast cancer development and metastasis in vivo (EGFR, CASP4 and VEGFA).

Original languageEnglish
Pages (from-to)2307-2315
Number of pages9
JournalRussian Chemical Bulletin
Volume67
Issue number12
DOIs
StatePublished - 1 Dec 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.

Funding

This work was financially supported by the Ministry of Education and Science of the Russian Federation (Federal Target Program "Research and Development in the Priority Areas of the Science and Engineering Sector of Russia for the 2014—2020 years"; UIPNI RFMEFI61316X0058).

FundersFunder number
UIPNIRFMEFI61316X0058
Ministry of Education and Science of the Russian Federation

    Keywords

    • ELOVL6
    • EMT
    • MCF7
    • MDA-MB-231
    • breast cancer
    • epithelial-mesenchymal transition
    • inhibitor
    • metastasis

    Fingerprint

    Dive into the research topics of 'The effect of ELOVL6 fatty acid elongase inhibition on the expression of genes associated with the metastasis of breast cancer'. Together they form a unique fingerprint.

    Cite this